Q2 EPS Forecast for Ocular Therapeutix Decreased by Analyst

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities researchers at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Ocular Therapeutix in a research report issued on Tuesday, May 6th. HC Wainwright analyst Y. Chen now expects that the biopharmaceutical company will post earnings of ($0.37) per share for the quarter, down from their previous forecast of ($0.29). HC Wainwright has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix's Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.48) EPS.

Other research analysts also recently issued research reports about the company. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th. William Blair began coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating for the company. Needham & Company LLC decreased their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $16.25.

Ocular Therapeutix Trading Down 2.2%

Shares of OCUL traded down $0.16 during mid-day trading on Thursday, reaching $7.23. The company's stock had a trading volume of 805,557 shares, compared to its average volume of 1,417,382. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix has a 52 week low of $4.79 and a 52 week high of $11.78. The company's fifty day moving average price is $7.46 and its two-hundred day moving average price is $8.23. The stock has a market cap of $1.15 billion, a PE ratio of -5.48 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million for the quarter, compared to analysts' expectations of $16.89 million.

Insider Buying and Selling

In related news, Director Richard L. Md Lindstrom purchased 10,000 shares of Ocular Therapeutix stock in a transaction dated Thursday, May 8th. The stock was purchased at an average cost of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the acquisition, the director now directly owns 172,704 shares of the company's stock, valued at $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the transaction, the insider now owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. The trade was a 0.61% decrease in their position. The disclosure for this sale can be found here. 3.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Ocular Therapeutix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new stake in shares of Ocular Therapeutix during the fourth quarter valued at $1,722,000. Charles Schwab Investment Management Inc. lifted its position in Ocular Therapeutix by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock valued at $9,663,000 after purchasing an additional 21,025 shares during the period. Barclays PLC boosted its holdings in Ocular Therapeutix by 37.1% in the third quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock worth $4,451,000 after purchasing an additional 138,441 shares during the last quarter. RoundAngle Advisors LLC bought a new stake in Ocular Therapeutix in the 4th quarter worth approximately $1,695,000. Finally, Rosalind Advisors Inc. lifted its holdings in shares of Ocular Therapeutix by 27.5% during the 4th quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock valued at $9,639,000 after buying an additional 243,700 shares during the period. 59.21% of the stock is owned by institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.